Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05119335 · ClinicalTrials.gov registry record · Phase 1
A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
A Phase 1 study, sponsored by NiKang Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
NCT05119335 is a Phase 1 study that was terminated before completion, run by NiKang Therapeutics. The registered enrollment target is 120 participants.
The verdict
NCT05119335, a Phase 1 study, was terminated before completion, sponsored by NiKang Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
Study Summary
The goal of the Phase 1 portion is to identify the maximum tolerated dose (MTD) and/or the recommended doses for expansion (RDEs) of NKT2152. The Phase 2 portion will evaluate the efficacy of NKT2152 in ccRCC.
Interventions
- DRUG Oral NKT2152
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2021-10-26 |
| Est. Completion | 2025-09-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05119335
The ClinicalTrials.gov registry entry for NCT05119335 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NiKang Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Oral NKT2152 is the first listed.
NCT05119335 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05119335 about?
NCT05119335 is a clinical study titled "A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma". The goal of the Phase 1 portion is to identify the maximum tolerated dose (MTD) and/or the recommended doses for expansion (RDEs) of NKT2152. The Phase 2 portion will evaluate the efficacy of NKT2152 in ccRCC.
What is the current status of trial NCT05119335?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2021-10-26. Estimated completion is 2025-09-30.
What interventions are being tested in trial NCT05119335?
The interventions under investigation include: Oral NKT2152 (DRUG).
Who is sponsoring clinical trial NCT05119335?
This trial is sponsored by NiKang Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.